Extensive Neurology Expertise

In recent years, major advances are occurring on multiple fronts in neuroscience, including deeper understanding of the disease biology, the ability cross the blood brain barrier, optimized approaches to clinical trials, more precise endpoints and a more flexible regulatory structure that understands the desperate need for new therapeutics. These advances have not only fueled growth in the neuroscience pipeline, as analyzed by Lumanity in Figure 1, but have also spurred a resurgence in pharmaceutical investment, evident in steadily increasing transaction values over the past four years. See Figure 2.

While advances in neurosciences mitigate some of the scientific and clinical/regulatory risk, meaningful commercial risk remains. Navigating this landscape requires companies to make strategic decisions at key inflection points during the development and commercialization of assets and portfolios. These decisions are crucial for defining, establishing, and demonstrating clinical relevance and value to a complex set of key stakeholders including physicians, patients and caregivers, and payers.

Lumanity offers extensive experience-based strategic guidance and insights in the field of neuroscience. Our goal is to provide our clients with actionable solutions that de-risk and optimize the development and commercialization of therapies, ultimately improving the lives of patients who are impacted across a range of conditions.